Assetmark Inc. Acquires 4,570 Shares of Cencora, Inc. $COR

Assetmark Inc. boosted its holdings in Cencora, Inc. (NYSE:COR) by 6.8% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 71,851 shares of the company’s stock after buying an additional 4,570 shares during the period. Assetmark Inc.’s holdings in Cencora were worth $22,571,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of COR. Kemnay Advisory Services Inc. acquired a new stake in Cencora during the 4th quarter worth $25,000. Oakworth Capital Inc. acquired a new position in shares of Cencora in the 4th quarter valued at $26,000. Elyxium Wealth LLC acquired a new position in shares of Cencora in the 4th quarter valued at $27,000. Archer Investment Corp boosted its position in shares of Cencora by 134.3% in the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after purchasing an additional 47 shares during the last quarter. Finally, Motiv8 Investments LLC bought a new position in shares of Cencora in the 4th quarter worth $29,000. 97.52% of the stock is owned by institutional investors.

Cencora Price Performance

NYSE COR opened at $307.72 on Friday. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95. The stock has a market cap of $59.87 billion, a price-to-earnings ratio of 23.60, a PEG ratio of 1.71 and a beta of 0.58. The business has a 50 day simple moving average of $279.98 and a 200 day simple moving average of $317.68. Cencora, Inc. has a 52-week low of $244.82 and a 52-week high of $377.54.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). The company had revenue of $78.36 billion during the quarter, compared to the consensus estimate of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Analysts anticipate that Cencora, Inc. will post 17.79 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were given a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.8%. The ex-dividend date of this dividend was Friday, May 15th. Cencora’s payout ratio is currently 18.40%.

Cencora declared that its board has authorized a stock repurchase program on Thursday, May 21st that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the company to repurchase up to 3.9% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Analysts Set New Price Targets

COR has been the subject of a number of recent analyst reports. Weiss Ratings downgraded Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, June 30th. Bank of America raised their target price on Cencora from $280.00 to $285.00 and gave the stock a “neutral” rating in a report on Wednesday, June 24th. Barclays decreased their target price on Cencora from $425.00 to $350.00 and set an “overweight” rating for the company in a research report on Wednesday, June 10th. William Blair started coverage on Cencora in a research note on Tuesday, April 28th. They issued a “market perform” rating for the company. Finally, Wells Fargo & Company cut their price target on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a research report on Monday, May 11th. Eleven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $367.75.

Insiders Place Their Bets

In related news, Director Lauren M. Tyler bought 550 shares of Cencora stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average cost of $270.23 per share, with a total value of $148,626.50. Following the purchase, the director owned 4,359 shares in the company, valued at approximately $1,177,932.57. This trade represents a 14.44% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.38% of the company’s stock.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.